{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:41:35Z","timestamp":1789656095625,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2021LCZD01"],"award-info":[{"award-number":["2021LCZD01"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20224BAB206005"],"award-info":[{"award-number":["20224BAB206005"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12072-024-10666-6","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T14:02:14Z","timestamp":1719237734000},"page":"1110-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis"],"prefix":"10.1007","volume":"18","author":[{"given":"Pei-Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Qian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-9004","authenticated-orcid":false,"given":"Zhen-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"10666_CR1","unstructured":"Hepatitis B. World Health Organisation. 2023. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed 12 July 2023"},{"issue":"2","key":"10666_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u2013398","journal-title":"J Hepatol"},{"issue":"4","key":"10666_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok A, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u20131599","journal-title":"Hepatology"},{"issue":"3","key":"10666_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","volume":"19","author":"RT Anderson","year":"2021","unstructured":"Anderson RT, Choi H, Lenz O, et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(3):463\u2013472","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10666_CR5","doi-asserted-by":"publisher","first-page":"733364","DOI":"10.3389\/fimmu.2021.733364","volume":"12","author":"J Ye","year":"2021","unstructured":"Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364","journal-title":"Front Immunol"},{"issue":"7","key":"10666_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jvh.13283","volume":"27","author":"MA Fonseca","year":"2020","unstructured":"Fonseca MA, Ling J, Al-Siyabi O, et al. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: a systematic review and meta-analysis. J Viral Hepat. 2020;27(7):650\u2013662","journal-title":"J Viral Hepat"},{"issue":"26","key":"10666_CR7","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682\u20132695","journal-title":"N Engl J Med"},{"issue":"3","key":"10666_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/hep.26436","volume":"58","author":"MJ Sonneveld","year":"2013","unstructured":"Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58(3):872\u2013880","journal-title":"Hepatology"},{"issue":"7","key":"10666_CR9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","volume":"136","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136(7):2169\u20132179.e4","journal-title":"Gastroenterology"},{"issue":"12","key":"10666_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206\u20131217","journal-title":"N Engl J Med"},{"issue":"3","key":"10666_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-019-09991-y","volume":"14","author":"CH Chen","year":"2020","unstructured":"Chen CH, Hu TH, Wang JH, et al. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int. 2020;14(3):317\u2013325","journal-title":"Hepatol Int"},{"issue":"12","key":"10666_CR12","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","volume":"68","author":"KS Liem","year":"2019","unstructured":"Liem KS, Fung S, Wong DK, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut. 2019;68(12):2206\u20132213","journal-title":"Gut"},{"issue":"4","key":"10666_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014;61(4):777\u2013784","journal-title":"J Hepatol"},{"issue":"3","key":"10666_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"M Bourliere","year":"2017","unstructured":"Bourliere M, Rabiega P, Ganne-Carrie N, et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2(3):177\u2013188","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"46","key":"10666_CR15","doi-asserted-by":"publisher","first-page":"10210","DOI":"10.3748\/wjg.v22.i46.10210","volume":"22","author":"LT He","year":"2016","unstructured":"He LT, Ye XG, Zhou XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon alpha-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol. 2016;22(46):10210\u201310218","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10666_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","volume":"150","author":"P Marcellin","year":"2016","unstructured":"Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis b surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134-144.e10","journal-title":"Gastroenterology"},{"issue":"2","key":"10666_CR17","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","volume":"20","author":"SG Lim","year":"2022","unstructured":"Lim SG, Yang WL, Ngu JH, et al. Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT. Clin Gastroenterol Hepatol. 2022;20(2):e228\u2013e250","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10666_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/jvh.13722","volume":"29","author":"J Chu","year":"2022","unstructured":"Chu J, Huang Y, Xie D, et al. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients. J Viral Hepatitis. 2022;29(9):765\u2013776","journal-title":"J Viral Hepatitis"},{"issue":"3","key":"10666_CR19","doi-asserted-by":"publisher","first-page":"306.e7","DOI":"10.1016\/j.cmi.2017.07.016","volume":"24","author":"N Chuaypen","year":"2018","unstructured":"Chuaypen N, Posuwan N, Chittmittraprap S, et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin Microbiol Infect. 2018;24(3):306.e7-306.e13","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10666_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12072-020-10095-1","volume":"15","author":"W Xu","year":"2021","unstructured":"Xu W, Li Q, Huang C, et al. Efficacy of peg-interferon-nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB. Hepatol Int. 2021;15(1):51\u201359","journal-title":"Hepatol Int"},{"key":"10666_CR21","doi-asserted-by":"publisher","first-page":"894410","DOI":"10.3389\/fimmu.2022.894410","volume":"13","author":"WX Wang","year":"2022","unstructured":"Wang WX, Jia R, Gao YY, et al. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-alpha in NA-suppressed chronic hepatitis B patients. Front Immunol. 2022;13:894410","journal-title":"Front Immunol"},{"issue":"5","key":"10666_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/apt.14862","volume":"48","author":"H Chan","year":"2018","unstructured":"Chan H, Messinger D, Papatheodoridis GV, et al. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018;48(5):547\u2013555","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10666_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, et al. HBsAg loss with Peg-interferon Alfa-2a in hepatitis b patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol. 2018;6(1):25\u201334","journal-title":"J Clin Transl Hepatol"},{"issue":"13","key":"10666_CR24","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen \u2264 1500 IU\/mL: an observational study. World J Gastroenterol. 2020;26(13):1525\u20131539","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10666_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/hep.32231","volume":"75","author":"NA Terrault","year":"2022","unstructured":"Terrault NA, Wahed AS, Feld JJ, et al. Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort. Hepatology. 2022;75(3):709\u2013723","journal-title":"Hepatology"},{"key":"10666_CR26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71","journal-title":"BMJ"},{"key":"10666_CR27","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. 2023. www.training.cochrane.org\/handbook"},{"issue":"11","key":"10666_CR28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/jvh.13599","volume":"28","author":"F De Ridder","year":"2021","unstructured":"De Ridder F, Sonneveld MJ, Lenz O, et al. Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance\u2014suggesting a valuable endpoint for early development HBV trials. J Viral Hepatitis. 2021;28(11):1563\u20131569","journal-title":"J Viral Hepatitis"},{"issue":"4","key":"10666_CR29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/apt.15098","volume":"49","author":"KS Liem","year":"2019","unstructured":"Liem KS, van Campenhout MJH, Xie Q, et al. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharm Ther. 2019;49(4):448\u2013456","journal-title":"Aliment Pharm Ther"},{"issue":"7","key":"10666_CR30","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/infdis\/jiy272","volume":"218","author":"IC Lee","year":"2018","unstructured":"Lee IC, Yang SS, Lee CJ, et al. Incidence and predictors of HBsAg loss after peginterferon therapy in HBeAg-negative chronic hepatitis B: a multicenter long-term follow-up study. J Infect Dis. 2018;218(7):1075\u20131084","journal-title":"J Infect Dis"},{"issue":"3","key":"10666_CR31","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.clinthera.2020.12.022","volume":"43","author":"C Hu","year":"2021","unstructured":"Hu C, Song Y, Tang C, et al. Effect of pegylated interferon plus tenofovir combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e antigen -positive chronic hepatitis B: a real-world experience. Clin Ther. 2021;43(3):572-581.e3","journal-title":"Clin Ther"},{"issue":"1","key":"10666_CR32","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","volume":"7","author":"J Huang","year":"2017","unstructured":"Huang J, Zhang K, Chen W, et al. Switching to PegIFNalpha-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Sci Rep. 2017;7(1):13383","journal-title":"Sci Rep"},{"issue":"21","key":"10666_CR33","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387(21):1957\u20131968","journal-title":"N Engl J Med"},{"issue":"1","key":"10666_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/jcm12010361","volume":"12","author":"F Wu","year":"2023","unstructured":"Wu F, Wang Y, Cui D, et al. Short-term Peg-IFN alpha-2b Re-treatment induced a high functional cure rate in patients with HBsAg recurrence after stopping Peg-IFN alpha-based regimens. J Clin Med. 2023;12(1):361","journal-title":"J Clin Med"},{"key":"10666_CR35","doi-asserted-by":"publisher","first-page":"104783","DOI":"10.1016\/j.antiviral.2020.104783","volume":"177","author":"A Koffas","year":"2020","unstructured":"Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res. 2020;177:104783","journal-title":"Antiviral Res"},{"issue":"12","key":"10666_CR36","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","volume":"63","author":"SH Ahn","year":"2018","unstructured":"Ahn SH, Marcellin P, Ma X, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon Alfa-2a: week 120 analysis. Dig Dis Sci. 2018;63(12):3487\u20133497","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10666_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000525518","volume":"11","author":"SK Kim","year":"2022","unstructured":"Kim SK, Fujii T, Kim SR, et al. Hepatitis B virus treatment and hepatocellular carcinoma: controversies and approaches to consensus. Liver Cancer. 2022;11(6):497\u2013510","journal-title":"Liver Cancer"},{"issue":"4","key":"10666_CR38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2016.05.024","volume":"65","author":"J Sun","year":"2016","unstructured":"Sun J, Ma H, Xie Q, et al. Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: a randomized controlled study. J Hepatol. 2016;65(4):674\u2013682","journal-title":"J Hepatol"},{"issue":"4","key":"10666_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12072-015-9644-y","volume":"9","author":"H Peng","year":"2015","unstructured":"Peng H, Wei F, Liu JY, et al. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. Hepatol Int. 2015;9(4):543\u2013557","journal-title":"Hepatol Int"},{"issue":"1","key":"10666_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12879-023-08443-1","volume":"23","author":"Q Tang","year":"2023","unstructured":"Tang Q, Ye J, Zhang Y, et al. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonalpha and decision process based on response-guided therapy strategy. BMC Infect Dis. 2023;23(1):456","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10666_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","volume":"77","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Heo J, Kumada H, et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol. 2022;77(4):967\u2013977","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10666-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T06:21:25Z","timestamp":1722666085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10666-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10666"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10666-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pei-Xin Zhang, Qian-Qian Tang, Jie Zhu, Wan-Yu Deng and Zhen-Hua Zhang declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}